Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults

Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years

(2016) Hung Fu Tseng et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

(2016) Anthony L. Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults

(2016) Roman Chlibek et al.   VACCINE

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

(2015) Himal Lal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination

(2015) Geert Leroux-Roels et al.   VACCINE

Persistence of the Immune Response to an Adjuvanted Herpes Zoster Subunit Vaccine in Healthy Older Adults: Modeling of Vaccine-Induced Immune Response, Data From a 6-Year Follow-Up Study

(2015) Himal Lal et al.   Open Forum Infectious Diseases

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults by Region: Results of the Phase 3 ZOE-50 Trial

(2015) Anthony L Cunningham et al.   Open Forum Infectious Diseases

Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study

(2014) Roman Chlibek et al.   VACCINE

Quantification of risk factors for herpes zoster: population based case-control study

(2014) Harriet J Forbes et al.   BMJ-British Medical Journal

Pathogenesis and Current Approaches to Control of Varicella-Zoster Virus Infections

(2013) A. A. Gershon et al.   CLINICAL MICROBIOLOGY REVIEWS

Incidence of herpes zoster in patients with altered immune function

(2013) S.-Y. Chen et al.   INFECTION

Herpes Zoster

(2013) Jeffrey I. Cohen   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years

(2012) K. E. Schmader et al.   CLINICAL INFECTIOUS DISEASES

Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems

(2011) Nathalie Garçon et al.   Expert Review of Vaccines

Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors

(2010) G. N. Malavige et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Zoster Vaccine: Current Status and Future Prospects

(2010) Michael N. Oxman   CLINICAL INFECTIOUS DISEASES

H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses

(2010) Philippe Moris et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Optimization and Limitations of Use of Cryopreserved Peripheral Blood Mononuclear Cells for Functional and Phenotypic T-Cell Characterization

(2009) A. Weinberg et al.   Clinical and Vaccine Immunology

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆

(2009) Marie-Pierre David et al.   GYNECOLOGIC ONCOLOGY

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

(2008) Pierre Vandepapelière et al.   VACCINE